Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 F... ( JERSEY CITY N.J. Feb. 15 201...)

Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 Fiscal Year

Date:2/15/2013

JERSEY CITY, N.J., Feb. 15, 2013 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2012. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 14, 2013.

Financial Results:

Revenues for the three and six months ended December 31, 2012 were $3,314,768 and $5,919,531, respectively, representing a 56% and a 62% increase over the revenues realized in the comparable periods of fiscal year 2012. In both periods the increase in revenues led to a 60% increase in gross profit. The increase in revenue was mainly attributable to the increase in sales of our main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Sales of Zhongtongan accounted for 93% of sales during the quarter ended December 31, 2012.

Aoxing Pharma completed a $10.2 million financing at the end of September 2012, which allowed it to make some crucial investments in the future of its business. Operating expenses, therefore, were swelled during the second quarter of fiscal 2013 by two categories of targeted investment:

Research and development ("R&D") expenses were $1,090,104 during the three months ended December 31, 2012 and $1,219,659 during the six month period then ended, in both cases representing a several fold increase over R&D expense in fiscal 2012.
Selling expenses in the amount of $1,706,202 incurred during the three months ended December 31, 2012 and $2,314
'/>"/>

SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Aoxing Pharmaceutical Company Announces Management Change
2. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For First Quarter Of 2013 Fiscal Year
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company

Post Your Comments:

(Date:5/21/2013)... , May 21, 2013 Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...

(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue: ... Optical Coherence Tomography (OCT) ... OBJECTIVES BCC,s ... offer synopsis of the current and future ...

(Date:5/21/2013)... Fla. , May 21, 2013 Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...

[0] Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference [0] Global Markets and Technologies for Optical Coherence Tomography (OCT)[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...

... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...

Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5 Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6 FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2 FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S.

(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...

(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...

(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...

(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2 Health News:GW launches center to address health disparities in the Latino immigrant community 2 Health News:GW launches center to address health disparities in the Latino immigrant community 3 Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3

[0] Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis [0] GW launches center to address health disparities in the Latino immigrant community [0] Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants

... Mass., Jan. 3 Boston Scientific,Corporation (NYSE: ... upcoming JP,Morgan Health Care Conference, in San Francisco., ... a 25-minute,presentation on Wednesday, January 9th, beginning at ... Executive Vice President,and Chief Financial Officer will join ...

... new retrospective study on the effects of N-acetylcysteine ... caused by acetaminophen poisoning has found that the ... higher incidence of liver recovery, and better survival ... issue of Liver Transplantation, a journal by John ...

... no raised risk to heart , , THURSDAY, Jan. 3 ... but controversial treatment for prostate cancer reduces long-term death ... as some specialists had feared. , In patients ... testosterone-lowering drugs and radiation therapy appeared to lower the ...

... ... issued, PARAMUS, N.J., Jan. ... forcing the conversion of its Series A,Convertible Preferred Stock. At 5:00 p.m., ... of common stock. All of the issued and outstanding shares of Series,A ...

... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and ... that Duane DeSisto, Chief Executive,Officer, will participate in ... scheduled to present an overview of the Company,at ... 2008 at The Westin St.,Francis Hotel in San ...

... is a former Officer of Aetna, Inc., ... HSKA ) today announced that Ms. Louise McCormick ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), "We pride ourselves on ... Board consisting of high quality, independent Directors,is critical ...

Cached Medicine News:Health News:Boston Scientific to Participate in JP Morgan Health Care Conference 2 Health News:Treatment with NAC is associated with better outcomes for children with liver failure 2 Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2 Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3 Health News:Smart Balance Announces Conversion of Convertible Preferred Stock 2 Health News:Louise McCormick Joins Heska's Board of Directors 2 Health News:Louise McCormick Joins Heska's Board of Directors 3

Boston Scientific to Participate in JP Morgan Health Care Conference Treatment with NAC is associated with better outcomes for children with liver failure Combo Therapy Cuts Prostate Cancer Death Rates Smart Balance Announces Conversion of Convertible Preferred Stock Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008 Louise McCormick Joins Heska's Board of Directors

Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...

... panels mounted on powder-coated steel ... free-standing modular cleanroom that meets ... Optional ceiling HEPA filter/fan units, ... to customer requirements. Negative-pressure ventilation, ...

... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...

Inquire...

Medicine Products:

TXG Series Stool 1G41 Modular Hardwall Clean Room BioSafe Clean Room; 304 Stainless Steel Discovery 100 Ultracentrifuges